Interleukin 6 and C-reactive protein in esophageal cancer

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1583-1590

  Groblewska, Magdalena ^a   Mroczko, Barbara ^a   Sosnowska, Dorota ^b   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Solec Hospital   (Poland)

Author keywords

Adenocarcinoma of esophagus; C reactive protein; Esophageal cancer; Esophageal squamous cell cancer; Interleukin 6

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT;

BARRETT ESOPHAGUS; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHEMORADIOTHERAPY; DRUG EFFICACY; ESOPHAGUS CANCER; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; TISSUE LEVEL; TUMOR GROWTH;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERLEUKIN-6; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864383761     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.05.009     Document Type: Review

References (102)

1. Crew K.D., Neugut A. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004, 31:450-464.
2. Pohn H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
3. Parkin M.D., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
4. El-Shahat M., Lotfy M., Fahmy L., Abouel-Nour M.F., El-Kenawy Ael-M. Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Cancer Inst 2004, 16:224-230.
5. Vallbohmer D., Lenz H.J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006, 19:425-432.
6. Lundell L.R. Etiology and risk factors for esophageal carcinoma. Dig Dis 2010, 28:641-644.
7. Coleman M.P., Gatta G., Verdecchia A., et al. Eurocare-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003, 14:128-149.
8. Holmes R.S., Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007, 17:2-9.
9. Mayne S.T., Navarro S.A. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 2002, 132:3467S-3470S.
10. Lindblad M., Rodríguez L.A., Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005, 16:285-294.
11. Fass R., Sampliner R.E. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003, 63:555-564.
12. Hattori S., Muto M., Ohtsu A., et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 2003, 58:65-70.
13. Chang F., Syrjänen S., Shen Q., et al. Evaluation of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. Anticancer Res 2000, 20:3935-3940.
14. Lyronis I.D., Baritaki S., Bizakis I., Tsardi M., Spandidos D.A. Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers 2005, 20:5-10.
15. Yao P.F., Li G.C., Li J., et al. Evidence of human papilloma virus infection and its epidemiology in esophageal squamous cell carcinoma. World J Gastroenterol 2006, 12:1352-1355.
16. Zhang Y.X., Gui X.E., Zhong Y.H., Rong Y.P., Yan Y.J. Cancer in cohort of HIV-infected population: prevalence and clinical characteristics. J Cancer Res Clin Oncol 2011, 137:609-614.
17. Brockmann J.G., St Nottberg H., Glodny B., Heinecke A., Senninger N.J. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000, 6:4249-4252.
18. Shimada H., Nabeya Y., Tagawa M., et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003, 94:628-632.
19. Tillett W.S., Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-585.
20. Abernethy T.J., Avery O.T. The occurrence during acute infections of a protein not normally present in the blood. I. Distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus. J Exp Med 1941, 73:173-182.
21. Myles D.A., Rule S.A., DeLucas L.J., et al. Rotation function studies of human C-reactive protein. J Mol Biol 1990, 216:491-496.
22. Diehl E.E., Haines G.K., Radosevich J.A., Potempa L.A. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000, 319:79-83.
23. Potempa L.A., Siegel J.N., Fiedel B.A., Potempa R.T., Gewurz H. Expression, detection, and assay of neoantigen (neo-CRP) associated with a free, human C-reactive subunit. Mol Immunol 1987, 24:531-541.
24. Ying S.C., Gewurz H., Kinoshita C.M., Potempa L.A., Siegel J.N. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. J Immunol 1989, 143:221-228.
25. Macintyre S.S., Schultz D., Kushner I. Biosynthesis of C-reactive protein. Ann NY Acad Sci 1982, 389:76-87.
26. Claus D.R., Siegel J., Petras K., Osmand A.P., Gewurz H. Interactions of C-reactive protein with the first component of human complement. J Immunol 1977, 119:187-192.
27. Tucci A., Goldberger G., Whitehead A.S., Kay R.M., Woods D.E., Colten H.R. Biosynthesis and postsynthetic processing of human C-reactive protein. J Immunol 1983, 131:2416-2419.
28. Weinhold B., Ruther U. Interleukin-6-dependent and independent regulation of the human C-reactive protein gene. Biochem J 1997, 327:425-429.
29. Zhang D., Jiang S.L., Rzewnicki D., Samols D., Kushner I. C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 1995, 310:143-148.
30. Baumann H., Schendel P. Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 1991, 266:20424-20427.
31. Gresser I., Delers F., Tran Quangs N., et al. Tumor necrosis factor induces acute phase protein in rats. J Biol Regul Homeost Agents 1987, 1:173-176.
32. Mackiewicz A., Ganapathi M.K., Schultz D., et al. Transforming growth factor B1 regulates production of acute phase proteins. Proc Natl Acad Sci U S A 1990, 87:1491-1495.
33. Kuta A.E., Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 1986, 164:321-326.
34. Egenhofer C., Alsdorff K., Fehsel K., Kolb-Bachofen V. Membrane associated C-reactive protein on rat liver macrophages is synthesized within the macrophages, expressed as neo-C-reactive protein and bound through a C-reactive protein-specific membrane receptor. Hepatology 1995, 18:1216-1223.
35. Kang D.H., Park S.K., Lee I.K., Johnson R.J. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005, 16:3553-3562.
36. Dong Q., Wright J.R. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996, 156:4815-4820.
37. Gould J.M., Weiser J.N. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001, 69:1747-1754.
38. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001, 38:189-197.
39. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
40. Rota S., Yildirim B., Kaleli B., Aybek H., Duman K., Kaptanoǧlu B. C-reactive protein levels in non-obese pregnant women with gestational diabetes. Tohoku J Exp Med 2005, 206:341-345.
41. Wang C.S., Sun C.F. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009, 32:471-482.
42. Kishimoto T. Interleukin-6: discovery of pleiotropic cytokine. Arthritis Res Ther 2006, 8:S2.
43. Bihl M.P., Heinimann K., Rüdiger J.J., et al. Identification of a novel IL-6 isoform binding to the endogenous IL-6 receptor. Am J Resp Cell Mol Biol 2002, 27:48-56.
44. Bowcock A.M., Ray A., Erlich H.A., Sehgal P.B. The molecular biology of beta-2-interferon/interleukin 6 (IFN beta 2). Ann NY Acad Sci 1989, 557:345-352.
45. Hattori M., Abraham L.J., Northemann W., Fey G.H. Acute-phase reaction induces a specific complex between hepatic nuclear proteins and the interleukin 6 response element of the rat alpha 2-macroglobulin gene. Proc Natl Acad Sci U S A 1990, 87:2364-2368.
46. Helle M., Boeije L., Pascual-Salcedo D., Aarden L. Differential induction of interleukin-6 production by monocytes, endothelial cells and smooth muscle cells. Prog Clin Biol Res 1991, 367:61-71.
47. Van Meir E., Sawamura Y., Diserens A.C., Hamou M.F., de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 1990, 50:6683-6688.
48. Helle M., Brakenhoff J.P., De Groot E.R., Aarden L.A. Interleukin-6 is involved in interleukin 1-induced activities. Eur J Immunol 1988, 18:957-959.
49. Culig Z., Steiner H., Bartsch G. Hobisch A interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005, 95:497-505.
50. Salgado R., Junius S., Benoy I., et al. Circulating interleukin-6 predictors survival in patients with metastatic breast cancer. Int J Cancer 2003, 103:642-646.
51. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
52. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992, 62:S60-S65.
53. Bergui L., Schena M., Gaidano G., Riva M., Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 1989, 170:613-619.
54. Ishibashi T., Kimura H., Uchida T., Kariyone S., Friese P., Burstein S.A. Human interleukin 6 is a direct promoter for maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A 1989, 86:5953-5957.
55. Straneva J.E., van Besien K.W., Derigs G., Hoffman R. Is interleukin 6 the physiological regulator of thrombopoiesis?. Exp Hematol 1992, 20:47-50.
56. Hirano T., Yasukawa K., Harada H., et al. Complementary DNA for novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
57. Coussens L., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
58. Vakkila J., Lotze M. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004, 4:641-648.
59. Zeh Hr, Lotze M. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005, 28:1-9.
60. Zhang X.G., Klein B., Bataille R. Interleukin 6 is a potent myeloma cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74:11-13.
61. Nachbaur D.M., Herold M., Maneschg A., Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991, 62:54-58.
62. Hata H., Xiao H., Petrucci M.T., Woodliff J., Chang R., Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993, 81:3357-3364.
63. Eustace D., Han X., Gooding R., Rowbottom A., Riches P., Heyderman E. Interleukin-6 (IL6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993, 50:15-19.
64. Chen L., Mory Y., Zilberstein A., Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β. Proc Natl Acad Sci 1988, 85:8037-8041.
65. Takizawa H., Ohtoshi T., Ohta K., et al. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 1993, 1553:4175-4181.
66. Herrmann F., Andreeff M., Gruss H.J., Brach M.A., Lübbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 1991, 78:2070-2074.
67. Huang S., Wu M., Wang H., Yang C., Kuo M., Lin J. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 2002, 17:1165-1169.
68. Ravishankaran P., Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011, 9:18-23.
69. Bellone S., Watts K., Cane' S., et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol 2005, 98:92-98.
70. Zakrzewska I., Pozański J. Changes of serum IL-6 and CRP after chemotherapy in patients with ovarian carcinoma. Pol Merkuriusz Lek 2001, 11:210-213.
71. Negrier S., Perol D., Menetrier-Caux C., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6. J Clin Oncol 2005, 23:1044-1045.
72. Kim D.K., Oh S.Y., Kwon H.C., et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009, 9:155-163.
73. Groblewska M., Mroczko B., Wereszczyńska-Siemiatkowska U., et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008, 46:1423-1428.
74. Mroczko B., Groblewska M., Gryko M., Kedra B., Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010, 24:256-261.
75. Songür N., Kuru B., Kalkan F., Ozdilekcan C., Cakmak H., Hizel N. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004, 90:196-200.
76. Łukaszewicz-Zajac M., Mroczko B., Gryko M., Kedra B., Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 2011, 11:89-96.
77. Allin K.H., Nordestgaard B.G., Flyger H., Bojesen S.E. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 2011, 13:R55.
78. Nozoe T., Iguchi T., Adachi E., Matsukuma A., Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today 2011, 41:510-513.
79. Oka M., Hirose K., Iizuka N., et al. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995, 15:1005-1009.
80. Oka M., Iizuka N., Yamamoto K., et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996, 16:1001-1006.
81. Oka M., Iizuka N., Yamamoto K., et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996, 56:2776-2780.
82. Leu C.M., Wong F.H., Chang C., Huang S.F., Hu C.P. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22:7809-7818.
83. Deans D.A., Wigmore S.J., Gilmour H., Paterson-Brown S., Ross J.A., Fearon K.C. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006, 95:1568-1575.
84. Nozoe T., Korenaga D., Futatsugi M., Saeki H., Maehara Y., Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor marker. Cancer Lett 2003, 192:89-95.
85. Motoyama S., Miura M., Hinai Y., Maruyama K., Murata K., Ogawa J. C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. World J Surg 2010, 34:1001-1007.
86. Wang L.S., Chow K.C., Wu C.W. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999, 80:1617-1622.
87. Hayama S., Okushiba S., Shichinohe T., Hirano S., Tanaka E., Kondo S. Esophageal carcinosarcoma presenting as a fever with elevated serum interleukin-6. Ann Thorac Surg 2011, 91:1288-1290.
88. Krzystek-Korpacka M., Matusiewicz M., Diakowska D., et al. Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008, 46:359-364.
89. Gockel I., Dirksen K., Messow C.M., Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006, 12:3746-3750.
90. Shimada H., Nabeya Y., Okazumi S., et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248-252.
91. Nozoe T., Saeki H., Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001, 182:197-201.
92. Guillem P., Triboulet J. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005, 18:146-150.
93. Łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus [Online] Available at: Accessed on 17 March 2012. http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2050.2011.01242.x/pdf.
94. Suchi K., Fujiwara H., Okamura S., et al. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011, 31:67-75.
95. Fujiwara H., Suchi K., Okamura S., et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011, 103:62-68.
96. Akiyama T., Yoneda M., Maeda S., Nakajima A., Koyama S., Inamori M. Visceral obesity and the risk of Barrett's esophagus. Digestion 2011, 83:142-145.
97. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
98. Zhang H.Y., Zhang Q., Zhang X., et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011, 300:G454-G460.
99. Dvorakova K., Payne C.M., Ramsey L., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004, 10:2020-2028.
100. Dvorak K., Chavarria M., Payne C.M., et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 2007, 13:5305-5313.
101. Konturek P.C., Kania J., Burnat G., Hahn E.G., Konturek S.J. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol 2005, 56:57-73.
102. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and metaanalysis. Gastroenterology 2003, 124:47-56.